Physician profile
Nader Balba
NPI 1013949254
$3,339.56
in general payments reported to CMS, 2019-2025
28 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $340 · 2021: $374 · 2022: $519 · 2023: $615 · 2024: $482 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788 · Education: $39.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.10 |
| Education | $39.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.01 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.26 | 2019-2025 | Xifaxan |
| Celgene Corporation | $363.05 | 2021-2024 | Zeposia |
| Pfizer INC. | $275.50 | 2021-2024 | |
| Genzyme Corporation | $199.27 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.53 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $133.26 | 2019-2025 | Stelara, Simponi, Remicade |
| Endogastric Solutions, INC | $124.99 | 2020 | |
| Braintree Laboratories, INC. | $118.47 | 2019-2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $110.83 | 2023-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $93.47 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $79.50 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $69.31 | 2022-2025 | |
| Celltrion USA INC. | $59.27 | 2024 | Zymfentra |
| Madrigal Pharmaceuticals | $51.46 | 2025 | Rezdiffra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $49.51 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $30.38 | 2022-2023 | Rebyota |
| Lilly USA, LLC | $25.97 | 2024 | Omvoh |
| Enterra Medical, INC. | $25.39 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.01 | 2025 | Iqirvo |
| Novo Nordisk INC | $18.82 | 2025 | Wegovy |
| Qol Medical, LLC | $17.49 | 2021 | |
| Daiichi Sankyo INC. | $16.77 | 2022 | |
| Pharmacosmos Therapeutics INC. | $16.42 | 2025 | Monoferric |
| Evoke Pharma, INC. | $14.72 | 2022 | |
| Boston Scientific Corporation | $14.24 | 2019 | |
| Alfasigma USA, INC. | $13.33 | 2020 | |
| Allergan, INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Balba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.